Lantheus Holdings, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LNTH in the last 30 days.
See all $LNTH insider activity →ETFs were net sellers of Lantheus (LNTH) for the fifth consecutive session on Oct. 22, with $11.7 million sold. The trend began on Oct. 16, totaling $59.6 million sold over five days. LNTH is a radiopharmaceutical company with a market cap of $6.5 billion, reporting TTM revenue of $1.56 billion. The stock trades at a P/E of 24.12 and has returned 49.96% YTD.
Lantheus and Curium received FTC Second Requests on October 21, extending the HSR waiting period. The companies expect to respond promptly and continue to anticipate closing the merger in the first half of 2027, subject to regulatory approvals.
Lantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Curium US Holdings LLC, a Delaware li
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning LNTH (Lantheus Holdings, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 4 bearish.
Recent LNTH coverage spans mergers & acquisitions, corporate actions and financial news.
Ongoing ETF net selling suggests near-term positioning pressure and potentially weaker incremental demand from passive/quant flows.
Regulatory scrutiny may delay the merger and create uncertainty.
The FTC review adds regulatory uncertainty to the Lantheus‑Curium merger.
JPMorgan Chase and Jefferies are leading a $4.25 billion financing deal for Lantheus Holdings. Citigroup adjusted its price target for JPMorgan to $350 from $360.
Potential downward pressure.
AlphAI scores every news story that mentions LNTH with an AI model for sentiment and relevance, and aggregates insider trades from Lantheus Holdings, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ETFs were net sellers of Lantheus (LNTH) for the fifth consecutive session on Oct. 22, with $11.7 million sold. The trend began on Oct. 16, totaling $59.6 million sold over five days. LNTH is a radiopharmaceutical company with a market cap of $6.5 billion, reporting TTM revenue of $1.56 billion. The stock trades at a P/E of 24.12 and has returned 49.96% YTD.
3 min readLantheus and Curium received FTC Second Requests on October 21, extending the HSR waiting period. The companies expect to respond promptly and continue to anticipate closing the merger in the first half of 2027, subject to regulatory approvals.
1 min readLantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“Lantheus” or the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among the Company, Curium US Holdings LLC, a Delaware li
1 min readJPMorgan Chase and Jefferies are leading a $4.25 billion financing deal for Lantheus Holdings. Citigroup adjusted its price target for JPMorgan to $350 from $360.
2 min readAvantis U.S. Small Cap Value ETF (AVUV) increased positions in 467 stocks and decreased 71, with $143.8M in gross trades. Top buys included Sprouts Farmers Market (SFM) and Lyft (LYFT). AVUV manages $31.13B in assets with an expense ratio of 0.25%.
2 min readLantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders A special meeting of stockholders (the “special meeting”) of Lantheus Holdings, Inc. (“Lantheus”) was held on October 14, 2026. A total of 57,184,503 shares of Lantheus common stock, out of a total of 65,299,875 shares
1 min readAnalysts downgraded several companies: Morgan Stanley cut Arch Capital (ACGL) to Equal-Weight, Piper Sandler downgraded AST SpaceMobile (ASTS) to Neutral, B of A Securities downgraded Pershing Square (PS) to Underperform, Mizuho downgraded Lantheus (LNTH) to Neutral, and HSBC downgraded Adobe (ADBE) to Hold. Price targets were also reduced for each company.
2 min readLantheus Holdings disclosed litigation and updated Morgan Stanley valuation analyses ahead of its October 14 stockholder meeting. Three complaints allege omissions in proxy statements, seeking to block the merger. The company provided supplemental disclosures but denies any deficiencies. Morgan Stanley's updated valuation ranges: DCF $88.10–$118.60/sh, comparable-company EV/EBITDA $63.85–$84.20/sh, analyst targets $98–$129.
1 min readLantheus Holdings, Inc. (LNTH) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on August 3, 2026, Lantheus Holdings, Inc., a Delaware corporation (“ Lantheus ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among the Company, Curium US Holdings LLC, a Delaw
2 min readLantheus (NASDAQ: LNTH) announced CMS granted Transitional Pass-Through payment status for PYLARIFY® TruVu (piflufolastat F 18), effective October 1, 2026. This designation enables separate reimbursement in hospital outpatient settings, supporting access to the diagnostic radiopharmaceutical for Medicare beneficiaries. PYLARIFY TruVu is a new formulation of Lantheus’ PSMA-targeted PET imaging agent for prostate cancer, with a permanent HCPCS code assigned for billing and reimbursement.
2 min read
